Latest Period
Q1 2026
Security Snapshot
Corvus Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (CRVS) Institutional Ownership
CUSIP: 221015100
13F Institutional Holders and Ownership History from Q1 2016 to Q1 2026
Institutions Reporting
164
Shares (Excl. Options)
69,974,523
Price
$14.63
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.0001 per share
- Symbol
- CRVS on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 69,974,523
- Total 13F value
- $1,023,112,733
- Portfolio coverage rank
- 0%
- Share change
- +22,456,136
- Value change
- +$357,447,187
- Number of holders
- 164
- Shares outstanding
- 91,091,040
- SEC-reported price per share
- $15.97
- Insider filing price
- $15.97
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- CRVS - Corvus Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 221015100.
- 164 institutions reported positions in Q1 2026.
- 5 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 125 to 164 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $359,443,900 to $1,023,112,733.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 164 institutions filings for Q1 2026.
Security key
221015100
Latest holder period
Q1 2026
13F holders
164
13D/G owners
5
CIK / CUSIP context first
Open Q1 2026 holders
CRVS full holder history
Corvus Pharmaceuticals, Inc. SEC filings
Corvus Pharmaceuticals, Inc. company facts
Corvus Pharmaceuticals, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 221015100:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
5
Security
CRVS
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 10% | -16% | $66,290,001 | -$9,057,756 | 8,609,091 | -12% | ORBIMED ADVISORS LLC | 23 Jan 2026 |
| Sirenia Capital Management LP | 7.5% | $101,657,601 | 6,831,828 | Sirenia Capital Management LP | 31 Mar 2026 | |||
| MILLER RICHARD A MD | 7.8% | +1.2% | $40,653,959 | +$5,781,901 | 6,085,922 | +17% | Richard A. Miller | 31 Dec 2025 |
| BlackRock, Inc. | 6.4% | +20% | $78,823,777 | +$20,076,866 | 5,387,818 | +34% | BlackRock, Inc. | 31 Mar 2026 |
| ADAMS STREET PARTNERS LLC | 3.9% | $25,222,243 | 3,275,616 | Adams Street Partners, LLC | 23 Jan 2026 |
As of 31 Mar 2026, 164 institutional investors reported holding 69,974,523 shares of Corvus Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (CRVS). This represents 77% of the company’s total 91,091,040 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
62%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 7.9% | 7,165,006 | 0% | 2.4% | $104,824,038 |
| BlackRock, Inc. | 6.8% | 6,160,422 | +22% | 0% | $90,126,972 |
| STATE STREET CORP | 3.9% | 3,565,992 | +28% | 0% | $52,170,463 |
| ADAMS STREET PARTNERS LLC | 3.6% | 3,275,616 | 0% | 18% | $47,922,262 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.6% | 3,234,538 | 0% | 0% | $47,321,291 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 3.2% | 2,917,300 | +8454% | 0% | $42,681,000 |
| Vivo Capital, LLC | 3.1% | 2,805,816 | +26% | 3.4% | $41,049,088 |
| MORGAN STANLEY | 2.7% | 2,498,825 | -30% | 0% | $36,557,808 |
| Deep Track Capital, LP | 2.7% | 2,491,539 | 0.75% | $36,451,216 | |
| WELLINGTON MANAGEMENT GROUP LLP | 2.5% | 2,318,517 | +637% | 0.01% | $33,919,904 |
| PERCEPTIVE ADVISORS LLC | 2.5% | 2,292,441 | +231% | 0.66% | $33,538,412 |
| Commodore Capital LP | 2.5% | 2,258,735 | 1.9% | $33,045,293 | |
| Foresite Capital Management VI LLC | 2% | 1,831,233 | +33% | 5.8% | $26,790,939 |
| BRAIDWELL LP | 1.9% | 1,752,798 | 0.86% | $25,643,435 | |
| GEODE CAPITAL MANAGEMENT, LLC | 1.9% | 1,712,741 | +16% | 0% | $25,064,026 |
| MPM BIOIMPACT LLC | 1.8% | 1,674,875 | -39% | 1.9% | $24,503,421 |
| GOLDMAN SACHS GROUP INC | 1.7% | 1,540,809 | +178% | 0% | $22,542,036 |
| Hood River Capital Management LLC | 1.5% | 1,335,109 | 0.2% | $19,532,645 | |
| Boxer Capital Management, LLC | 1.2% | 1,100,000 | 2.1% | $16,093,000 | |
| Polar Capital Holdings Plc | 1.2% | 1,070,174 | 0.07% | $15,656,646 | |
| Catalio Capital Management, LP | 0.98% | 891,933 | 2.7% | $13,048,980 | |
| MILLENNIUM MANAGEMENT LLC | 0.95% | 866,362 | +26% | 0.01% | $12,674,876 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 0.82% | 750,000 | 0.02% | $10,972,500 | |
| EMERALD ADVISERS, LLC | 0.75% | 686,216 | 0.32% | $10,039,340 | |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 0.74% | 669,895 | 0% | 0% | $9,800,564 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
41
Latest
Q1 2026
Rows shown
1-25 of 41
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 69,974,523 | $1,023,112,733 | +$357,447,187 | $14.63 | 164 |
| 2025 Q4 | 46,682,919 | $359,443,900 | +$38,829,151 | $7.70 | 125 |
| 2025 Q3 | 41,673,686 | $307,002,895 | +$4,353,875 | $7.37 | 101 |
| 2025 Q2 | 41,781,497 | $167,123,225 | +$27,653,733 | $4.00 | 92 |
| 2025 Q1 | 36,268,523 | $115,333,082 | -$7,370,970 | $3.18 | 87 |
| 2024 Q4 | 37,723,156 | $201,818,514 | +$34,704,752 | $5.35 | 85 |
| 2024 Q3 | 30,026,264 | $158,538,176 | +$12,733,385 | $5.28 | 61 |
| 2024 Q2 | 27,591,708 | $50,216,835 | +$17,655,345 | $1.82 | 46 |
| 2024 Q1 | 17,899,766 | $31,860,771 | -$2,279,392 | $1.78 | 46 |
| 2023 Q4 | 19,183,314 | $33,762,501 | +$90,871 | $1.76 | 46 |
| 2023 Q3 | 19,186,334 | $28,011,450 | -$1,230,958 | $1.46 | 52 |
| 2023 Q2 | 19,491,995 | $44,633,999 | +$707,708 | $2.29 | 51 |
| 2023 Q1 | 20,767,710 | $18,897,208 | -$183,902 | $0.91 | 35 |
| 2022 Q4 | 21,363,573 | $18,157,963 | -$606,364 | $0.85 | 38 |
| 2022 Q3 | 22,082,952 | $18,073,081 | -$3,458,421 | $0.82 | 38 |
| 2022 Q2 | 25,594,950 | $25,339,212 | -$3,279,778 | $0.99 | 39 |
| 2022 Q1 | 27,387,121 | $44,913,000 | -$1,201,434 | $1.64 | 52 |
| 2021 Q4 | 27,678,421 | $66,701,000 | -$7,831,144 | $2.41 | 58 |
| 2021 Q3 | 28,180,241 | $136,388,000 | +$22,907,893 | $4.84 | 55 |
| 2021 Q2 | 23,673,230 | $63,207,000 | +$8,569,595 | $2.67 | 44 |
| 2021 Q1 | 20,393,400 | $62,807,000 | +$12,093,812 | $3.08 | 45 |
| 2020 Q4 | 16,311,910 | $58,071,014 | -$3,250,489 | $3.56 | 34 |
| 2020 Q3 | 17,216,699 | $69,036,016 | -$11,684,715 | $4.01 | 33 |
| 2020 Q2 | 20,440,680 | $55,598,011 | -$392,205 | $2.72 | 34 |
| 2020 Q1 | 20,651,240 | $43,573,167 | -$3,308,904 | $2.11 | 36 |